

## Cervical surface or crypt (Non-core)

Cervical surface mucosal or crypt epithelial involvement (without cervical stromal invasion) does not affect tumour stage in the 2009 International Federation of Gynaecology and Obstetrics (FIGO) Staging System and is regarded as a non-core element.<sup>1</sup> However, it is a potential adverse risk factor for locoregional recurrence and may be taken into consideration for adjuvant radiotherapy.<sup>2</sup> In the Post Operative Radiation Therapy in Endometrial Carcinoma-2 (PORTEC-2) and Gynecology Oncology Group trial 99 (GOG #99) prospective randomised trials, patients with high-intermediate risk factors, including cervical surface or crypt involvement (FIGO 1988 Stage IIA), were found to have improved locoregional disease control (reduced recurrence rate) with postoperative radiation (vaginal brachytherapy or pelvic radiation).<sup>3-6</sup> While the above studies lacked an overall survival benefit, a recent large retrospective cohort (analysing over 14,000 patients) demonstrated improved overall survival in FIGO 1988 Stage IIA patients receiving adjuvant radiation.<sup>7</sup>

The current clinical practice guidelines of the American Society for Radiation Oncology and the Society of Gynecologic Oncology are based on the results of the PORTEC-2 and GOG #99 trials for adjuvant radiotherapy.<sup>8,9</sup>

## References

- 1 FIGO Committee on Gynecological Cancer (2009). Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. *Int. J. Gynecol. Obstet.* 105:103-104.
- 2 Singh N, Hirschowitz L, Zaino R, Alvarado-Cabrero I, Duggan MA, Ali-Fehmi R, Euscher E, Hecht JL, Horn LC, Ioffe O, Matias-Guiu X, McCluggage WG, Mikami Y, Ordi J, Parkash V, Quddus MR, Quick CM, Staebler A, Zaloudek C, Nucci M, Malpica A and Oliva E (2019). Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade). *Int J Gynecol Pathol* 38 Suppl 1(Iss 1 Suppl 1):S93-s113.
- 3 Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL and Creutzberg CL (2010). Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet* 375(9717):816-823.
- 4 Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA and Bell JG (2004). A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 92(3):744-751.
- 5 Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H and van Lent M (2000). Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. *Lancet* 355(9213):1404-1411.
- 6 Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens L, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit V and Nout RA (2018). Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. *Br J Cancer* 119(9):1067-1074.
- 7 Cahan B, Kim JH, Schultheiss TE, Wong JYC and Chen YJ (2018). Stage I and II endometrial adenocarcinoma: analysis of 2009 FIGO staging revision and impact on survival by adjuvant therapy. *Am J Clin Oncol* 41(3):302-306.

- 8 Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, Fleming G, Gaffney D, Greven K, Lu K, Miller D, Moore D, Petereit D, Schefter T, Small W, Jr., Yashar C and Viswanathan AN (2014). The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. *Pract Radiat Oncol* 4(3):137-144.
- 9 Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Herzog TJ and Shahin FA (2014). Endometrial cancer: a review and current management strategies: part II. *Gynecol Oncol* 134(2):393-402.